General
Preferred name
ENOXACIN
Synonyms
Enoxacin Sesquihydrate ()
AT-2266 hydrate ()
CI-919 hydrate ()
AT 2266 ()
CI 919 ()
Enoxacin hydrate ()
Pd107779 ()
NSC 629661 ()
Enoxacin ()
Enoxacin (hydrate) ()
Enoxacin (sesquihydrate) ()
AT-2266 (hydrate) ()
CI-919 (hydrate) ()
AT-2266, CI919, Pd107779, NSC 629661 ()
CI-919 ()
Flumark ()
Comprecin ()
PD 107779 ()
PD-107779 ()
NSC-758416 ()
AT-2266 ()
NSC-629661 ()
Penetrex ()
Enoxacin-d8 (hydrochloride) ()
P&D ID
PD001045
CAS
74011-58-8
84294-96-2
2930288-95-0
Tags
natural product
drug
available
Approved by
FDA
First approval
1991
Drug Status
investigational
approved
withdrawn
Drug indication
Antibacterial
Urinary tract infection
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Enoxacin was developed as a oral broad-spectrum fluoroquinolone antibacterial for the treatment of urinary tract infections and gonorrhea.
Enoxacin has been reported as an inhibitor of the interaction between the B2 subunit of vacuolar H+-ATPase (ATP6V1B2) and microfilaments , an interaction required for translocation of the ATPase to the plasma membrane. This process effects activation of osteoclasts and regulates bone resorption, making this interaction a novel target for pharmaceutical intervention to reduce the pathologies associated with bone-loss condtions . (GtoPdb)
Enoxacin has been reported as an inhibitor of the interaction between the B2 subunit of vacuolar H+-ATPase (ATP6V1B2) and microfilaments , an interaction required for translocation of the ATPase to the plasma membrane. This process effects activation of osteoclasts and regulates bone resorption, making this interaction a novel target for pharmaceutical intervention to reduce the pathologies associated with bone-loss condtions . (GtoPdb)
DESCRIPTION
Enoxacin hydrate is a synthetic antibiotic belonging to quinolone carboxylic acid compound. It is bactericidal and has a postantibiotischen effect. It is a broad-spectrum antibacterial agent and inhibited 90% Escherichia coli, Klebsiella sp., Aeromonas sp., Enterobacter spp., Serratia spp., Proteus mirabilis, and Morganella morganii at less than or equal to 0.8 micrograms/ml.
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
3
Organisms
3
Compound Sets
23
BOC Sciences Bioactive Compounds
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
MedChem Express Bioactive Compound Library
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
50
Molecular Weight
320.13
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
2
cLogP
0.66
TPSA
87.46
Fraction CSP3
0.4
Chiral centers
0.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Bacterial
DNA gyrase
Topoisomerase IV
Topo II
Topo IV
TOP2A
antibiotic
DNA/RNA Synthesis
MicroRNA
Topoisomerase
Pathway
Anti-infection
DNA Damage/DNA Repair
Cell Cycle/DNA Damage
Epigenetics
MOA
bacterial topoisomerase inhibitor
DNA gyrase inhibitor
Topoisomerase inhibitor
Indication
urinary tract infections, gonorrhea
ATC
J01MA04
Therapeutic Class
Antiinfective Agents
Solubility
DMSO:45mg/mL
Source data
